Udho Thadani to Blood Pressure
This is a "connection" page, showing publications Udho Thadani has written about Blood Pressure.
Connection Strength
0.585
-
The risk of cardiovascular side effects with anti-anginal drugs. Expert Opin Drug Saf. 2016 Dec; 15(12):1609-1623.
Score: 0.123
-
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008 Feb; 31(2):353-60.
Score: 0.066
-
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 04; 40(11):2006-12.
Score: 0.047
-
Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC Heart Fail. 2016 05; 4(5):348-56.
Score: 0.029
-
Hypertension and cardiovascular disease risk in women. Med Sci Sports Exerc. 1996 Jan; 28(1):7-8.
Score: 0.029
-
Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Am J Cardiol. 1992 Aug 01; 70(3):286-92.
Score: 0.023
-
Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991 Dec; 84(6):2398-408.
Score: 0.022
-
A multicenter comparison of isradipine and prazosin for treatment of essential hypertension. Cardiovasc Drugs Ther. 1990 Apr; 4(2):413-7.
Score: 0.020
-
Long-term bepridil monotherapy for angina pectoris. Am J Cardiol. 1988 Jun 01; 61(15):1210-3.
Score: 0.017
-
Isosorbide-5-mononitrate in angina pectoris: plasma concentrations and duration of effects after acute therapy. Clin Pharmacol Ther. 1987 Jul; 42(1):58-65.
Score: 0.016
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
Score: 0.015
-
Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. Am J Cardiol. 1985 Mar 15; 55(7):36C-42C.
Score: 0.014
-
Beta blockers in hypertension. Am J Cardiol. 1983 Nov 10; 52(9):10D-15D.
Score: 0.013
-
Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy. Circulation. 1980 Sep; 62(3):491-502.
Score: 0.010
-
Propranolol in angina pectoris: comparison of therapy given two and four times daily. Am J Cardiol. 1980 Jul; 46(1):117-23.
Score: 0.010
-
Are the clinical and hemodynamic events during exercise stress testing in invasive studies in patients with angina pectoris reproducible? Circulation. 1980 Apr; 61(4):744-50.
Score: 0.010
-
Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation. 1980 Mar; 61(3):526-35.
Score: 0.010
-
Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980 Feb; 68(2):243-50.
Score: 0.010
-
Cardiac performance at rest and during exercise in normal subjects. Bull Eur Physiopathol Respir. 1979 Sep-Oct; 15(5):935-49.
Score: 0.009
-
Clinical, hemodynamic and metabolic responses during pacing in the supine and sitting postures in patients with angina pectoris. Am J Cardiol. 1979 Aug; 44(2):249-56.
Score: 0.009
-
Propranolol in angina pectoris: duration of improved exercise tolerance and circulatory effects after acute oral administration. Am J Cardiol. 1979 Jul; 44(1):118-25.
Score: 0.009
-
Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979 Apr 05; 300(14):750-5.
Score: 0.009
-
Propranolol in the treatment of angina pectoris. Comparison of duration of action in acute and sustained oral therapy. Circulation. 1979 Mar; 59(3):571-9.
Score: 0.009
-
Influence of glyceryl trinitrate during supine and upright exercise in patients with angina pectoris. Br Heart J. 1978 Nov; 40(11):1229-36.
Score: 0.009
-
Hemodynamics at rest and during supine and sitting bicycle exercise in normal subjects. Am J Cardiol. 1978 Jan; 41(1):52-9.
Score: 0.008
-
Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Am J Cardiol. 1997 May 15; 79(10):1401-5.
Score: 0.008
-
Pulmonary veno-occlusive disease. Q J Med. 1975 Jan; 44(173):133-59.
Score: 0.007
-
Proceedings: Left ventricular pressure-volume changes during exercise-induced pain in patients with angina pectoris. Br Heart J. 1974 Oct; 36(10):1038.
Score: 0.007
-
Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973 Jan 20; 1(5846):138-42.
Score: 0.006
-
Effects of 1-epinephrine on hemodynamics and cardiac function in coronary disease: dose-response studies. Clin Pharmacol Ther. 1988 Mar; 43(3):308-16.
Score: 0.004
-
Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily. Am J Cardiol. 1981 May; 47(5):1123-7.
Score: 0.003
-
Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. Br Med J. 1976 Jul 03; 2(6026):7-9.
Score: 0.002
-
Cardiovascular effects of weight reduction in obese patients with angina pectoris. Br Heart J. 1974 Sep; 36(9):854-8.
Score: 0.002